Consultation On Draft Guidance Governing Public Release Of Clinical Information Contained In Drug Submissions And Medical Device Applications

SB
Smart & Biggar

Contributor

Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients. Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights. As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
Implementation will occur in 4 phases to take place over 4 years.
Canada Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

As previously reported, on December 9, 2017, Heath Canada released proposed amendments to the Food and Drug Regulations and Medical Devices Regulations providing for the public release of clinical information contained in drug submissions and medical device applications. On April 10, 2018, Health Canada published a draft guidance document addressing implementation of the proposed amended regulations. According to the guidance:

  • Implementation will occur in 4 phases to take place over 4 years. In the first phase, Health Canada plans to proactively publish clinical information contained in any (i) new drug submission (NDS) for a new active substance, (ii) supplemental new drug submission (SNDS) containing confirmatory trials, or (iii) application to switch an authorized medicinal ingredient to non-prescription status. By year 4, this will expand to clinical information in any NDS, SNDS, abbreviated new drug submission (ANDS), or supplemental abbreviated new drug submission (SANDS) as well as any Class III or IV medical device application.

  • Upon issuance of a negative regulatory decision, the publication process will be delayed 30 days for the manufacturer to seek reconsideration or an appeal. Publication will be initiated upon completion of any reconsideration or appeal.

  • The manufacturer will be notified by email of the list of documents that will be publically released and will have 20 days to propose redactions and de-identify the data. Data anonymization must be explained in a separate "Anonymization Report".

  • Redactions may be proposed for certain categories of clinical information that remain confidential business information ( previously reported).

  • Clinical information from past submissions will be available upon request through Health Canada's clinical information portal.

Health Canada is seeking stakeholder comments on the draft guidance, which may be submitted until June 25, 2018.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More